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Thiesson HC, Jensen BL, Bistrup C, Ottosen PD, McNeilly AD,
Andrew R, Seckl J, Skøtt O. Renal sodium retention in cirrhotic rats
depends on glucocorticoid-mediated activation of mineralocorticoid re-
ceptor due to decreased renal 11-HSD-2 activity. Am J Physiol Regul
Integr Comp Physiol 292: R625–R636, 2007. First published August 17,
2006; doi:10.1152/ajpregu.00418.2005.—Downregulation of the renal
glucocorticoid-metabolizing enzyme 11-hydroxysteroid dehydrogenase
type 2 (11-HSD-2) during liver cirrhosis may allow activation of the
mineralocorticoid receptor (MR) by glucocorticoids and contribute to
sodium retention. We tested this hypothesis in male Wistar rats with
decompensated liver cirrhosis and ascites 7 wk after bile duct ligation
(BDL). Renal 11-HSD-2 mRNA, protein, and activity were signifi-
cantly decreased in decompensated rats. The urinary Na/K ratio was
reduced by 40%. Renal epithelial sodium channel (ENaC) mRNA and
immunostaining were only slightly affected. Complete metabolic studies,
including fecal excretion, showed that the BDL rats had avid renal
sodium retention. Treatment of the BDL rats with dexamethasone sup-
pressed endogenous glucocorticoid production, normalized total sodium
balance and renal sodium excretion, and reduced ascites formation to the
same degree as direct inhibition of MR with K-canrenoate. Total potas-
sium balance was negative in the BDL rats, whereas renal potassium
excretion was unchanged. In the distal colon, expression of ENaC was
increased in BDL rats. Fecal potassium excretion was increased in
cirrhotic rats, and this was corrected by treatment with K-canrenoate but
not dexamethasone. We conclude that development of sodium retention
and decompensation in cirrhotic rats is associated with downregulation of
renal 11-HSD-2 activity and inappropriate activation of renal sodium
reabsorption by endogenous glucocorticoids. In addition, the overall
potassium loss in the BDL model is due to increased fecal potassium
excretion, which is associated with upregulation of ENaC in distal colon.
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DECOMPENSATED LIVER CIRRHOSIS is characterized by avid sodium
and water retention. Ascites formation is associated with a high
morbidity, and in humans there is a mortality rate of 50%
within 3 yr (3). In some patients, activation of the renin-
angiotensin-aldosterone-system contributes to sodium reten-
tion (7, 35, 42), but many patients exhibit low or normal
plasma renin and aldosterone concentrations (8, 18, 41, 43),
leaving the sodium retention unexplained. Interestingly, stud-
ies in rats have demonstrated transient downregulation of the
glucocorticoid-metabolizing enzyme 11-hydroxysteroid de-
hydrogenase type 2 (11-HSD-2) in the kidney 2–4 wk after
bile duct ligation (BDL), before cirrhosis and ascites develops
(1, 10). Glucocorticoids and aldosterone bind with equal affin-
ity to the mineralocorticoid receptor (MR) in vitro, and cortisol
(in humans) and corticosterone in (rats ad mice) circulate at
100–1,000 times the level of aldosterone in plasma (11, 15).
The selective access of aldosterone to the MR is ensured by
11-HSD-2, predominantly localized in epithelial mineralo-
corticoid target cells in the kidney and colon. 11-HSD-2
converts corticosterone and cortisol to their inactive 11-keto
metabolites, 11-dehydrocorticosterone and cortisone, respec-
tively. These findings led to the proposal that glucocorticoids
could contribute to excess activation of MR with progression
of liver cirrhosis (1, 10) and thereby mediate sodium retention
and potassium loss. Consistent with this, loss-of-function mu-
tations in the 11-HSD-2 gene (39) and inhibitors of 11-
HSD-2 activity (38) lead to sodium retention.
Based on existing data, 11-HSD-2 expression and activity
seem to be suppressed in the preascitic phase in the first 2–4
wk after BDL (1, 10). There are currently no data available on
the potential changes in 11-HSD-2 activity and its contribu-
tion to the marked sodium retention that occurs in later stages
of the disease when decompensation with ascites develops.
More importantly, intervention has not been tested. The present
study addressed directly the hypothesis that downregulation of
11-HSD-2 in distal nephron and/or colon contributes to so-
dium retention in BDL rats with decompensated liver cirrhosis.
Rats were examined 5 and 7 wk after BDL, when they suffered
from compensated and decompensated liver cirrhosis, respec-
tively (6, 26). Plasma and tissue levels of the renin-angioten-
sin-aldosterone system components and of 11-HSD-2 were
measured, and the findings were correlated with sodium and
potassium total balance studies. In addition, the functional
significance of endogenous glucocorticoids for sodium reten-
tion and potassium wasting was tested by suppression of
endogenous glucocorticoids by treatment with the glucocorti-
coid receptor-specific agonist dexamethasone.
MATERIALS AND METHODS
Animals and Surgical Protocol
Male Wistar rats were obtained from M & B (Ejby, Denmark). The
Danish Animal Experiments Inspectorate approved all experimental
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procedures, and all animals were treated according to the Guide for
the Care and Use of Laboratory Animals. The rats were fed a diet with
0.2% sodium and 1.0% potassium (Altromin 1324; Altromin Interna-
tional, Lage, Germany) and had free access to tap water. When rats
were in metabolic cages, food was administered as granules (diameter
1.7 mm) to avoid spillage into feces and urine collection vials.
Animals were anesthetized by subcutaneous injection with fentanyl
citrate (0.25 mg/kg), fluanisone (8 mg/kg), and diazepam (4 mg/kg).
The common bile duct was isolated and ligated, and 0.5 cm was
excised (26) or manipulated and left intact (sham surgery). Postoper-
ative pain was treated by administration of buprenorphin subcutane-
ously (0.1 mg/kg). We performed three experimental series in the
present study.
At the end of the different treatment protocols, the rats were
decapitated and trunk blood was collected. Organs were removed,
weighed, and snap frozen for later RNA and protein isolation. Ascites
volume was determined by aspiration of free fluid in the abdominal
cavity.
Series 1: 5-wk BDL rats. In the first series, six rats had BDL and
five rats were sham operated (sham). These rats were followed for
5 wk.
Series 2: 7-wk BDL rats. To study sodium balance in the decom-
pensated phase, the next groups of rats were followed for 7 wk (BDL,
n  18; sham, n  12). The rats were housed in individual metabolic
cages from day 42 to day 49 after BDL. Na, K, and water intake
and excretion were followed after a 2-day run-in period. Rats without
ascites were excluded from analysis in this series.
Series 3: 7-wk BDL-intervention. In the third series, we tested the
effect of dexamethasone and K-canrenoate on Na and K balance in
decompensated BDL rats (sham-vehicle, n 12; BDL vehicle, n
15; BDL  K-canrenoate, n  15; BDL  dexamethasone, n  15).
Rats received vehicle, dexamethasone (100 g kg1 day1; Decad-
ron, Merck Sharp & Dohme, Haarlem, The Netherlands), or K-
canrenoate (80 mg kg1 day1; Soldactone, Searle, Denmark) for 5
days in the decompensated stage with sodium retention (days 44–48).
A 48-h run-in period in metabolic cages was allowed before admin-
istration of drugs. Balance studies began 24 h before drug adminis-
tration. The experiment was terminated at 7 wk (day 49) after BDL.
Rats that did not complete the basal 24-h collections were excluded
from the data analysis.
Plasma and Urine Analyses
Plasma renin and atrial natriuretic peptide (ANP) concentrations
were measured by radioimmunoassay as described previously (9, 29).
Plasma aldosterone and corticosterone concentrations were measured
with commercial kits (Coat-A-Count Aldosterone, DPC, Los Angeles,
CA; rat corticosterone assay, Amersham Biotrak, Amersham, Buck-
inghamshire, UK). Tissue renin concentration was measured by ra-
dioimmunoassay as described previously (32). Bilirubin, alanine
amino transferase, bile acids, albumin, and creatinine were analyzed
using an analyzer (Cobas Mira; Roche Diagnostics, Basel, Switzer-
land). Platelet count, leucocytes, hematocrit, and hemoglobin were
analyzed on a Celltac MEK-6108K (Nihon Kohden, Tokyo, Japan).
Electrolytes were determined by flame photometry (IL 943 flame
photometer; Instrumentation Laboratory, Milan, Italy). Osmolality
was measured by freezing point depression (Osmomat 030D; Gono-
tec, Berlin, Germany). Sodium and potassium balances were calcu-
lated as the ratio between oral intake and the sum of losses in urine
and feces. To estimate fecal water content, feces were heated until
constant weight (24 h) at 100°C. Dried feces were then dissolved in 30
ml of 0.7 M HNO3, homogenized (Polytron PT300, Kinematica,
Kriens-Luzern, Switzerland), and gently shaken for 24 h. Subse-
quently, electrolytes were determined in the supernatant by flame
photometry. Creatinine clearance (Clcrea), which is a reliable measure
of glomerular filtration rate (GFR) in Wistar rats (40), was calculated
using urine collected over the last 24 h in a metabolic cage.
Isolation of RNA and Ribonuclease Protection Assay
Total RNA was isolated from rat organs with the Qiagen RNeasy
Midi Kit, and mRNA levels were estimated by A/T1 ribonuclease
protection assay (30, 36). Plasmids carrying sequences for renin (234
bp) and 11-HSD-2 (291 bp) have previously been cloned and
validated (22, 30). Partial rat cDNA encoding epithelial sodium
channel (ENaC) subunits was cloned by RT-PCR with the following
primer sequences (Invitrogen, Paisley, Scotland): -subunit, S 5-
ATTGACCTAGACCTTCAC-3 as 5-CAT GCGGTTGTGTTT-
GGA-3 (accession no. U54700, 263 bp; probe used for RNase
protection assay, 193 bp); -subunit, 5-AGGCTACACCTA-
CAAGGA-3 as 5-AGTTCATGGTCTTGAAGC-3 (accession no.
U35175, 222 bp); and -subunit, 5-GCTATTCTGCCGAAGAAC-3
as 5-TGGAGGTGCTGAGGATGG-3 (accession no. U37540, 146
bp). Primers were designed to anneal in regions without homology
and were synthesized with restriction sites for BamHI (sense) and
EcoRI (antisense) in the 5 direction (15 bp) to allow for directional
cloning in vector pSP73 (Promega, Rødovre, Denmark). Plasmids
were sequenced by T7 polymerase (Promega) on an ABI Prism
genetic analyzer with ready reaction mix from ABI. Plasmids were
linearized with HindIII and purified with a Qiagen PCR purification
kit. Plasmids yielded radiolabeled antisense cRNA transcripts by
incubation with SP6 polymerase (Promega) and [-32P]GTP (Amer-
sham) according to the Promega riboprobe in vitro transcription
protocol.
Western Immunoblot Analysis
Protein was isolated from distal colon and kidney as described
previously (30). Protein concentration was determined on a spectro-
photometer (Bio-Rad protein assay reagent). Protein separation and
immunoblotting for 11-HSD-2 was as described previously (30).
Immunohistochemical Staining for Renin, 11-HSD-2, and
ENaC -Subunit
In all three series, a limited number of sham and BDL rats were
fixed by retrograde perfusion of the aorta with 4% paraformaldehyde.
Tissue blocks incubated overnight in paraformaldehyde and were
embedded in paraffin using standard techniques. Sections (5 m) were
cut, deparaffinized, brought to a watery medium through successive
alcohol-buffer mixtures, and labeled with primary antibodies [rabbit
anti-rat renin (K. Poulsen, diluted 1:500); sheep anti-rat 11-HSD-2
(Ab 1296, Santa Cruz Biotechnology, diluted 1:2,000); rabbit anti-
ENaC -subunit (ENaCa11A, Biotrend, Ko¨ln, Germany)]. Secondary
antibodies were horseradish peroxidase coupled with goat anti-rabbit
immunoglobulin G (Sigma) and rabbit anti-sheep IgG (Sigma), both
diluted 1:500. The sections were stained with diaminobenzidine
(DAB substrate-chromogen system; DAKO, Glostrup, Denmark).
Negative controls were without primary antibody.
Measurement of 11-HSD-2 Activity
11-HSD-2 is a unidirectional dehydrogenase catalyzing the rapid
conversion of active corticosterone to inert 11-dehydrocorticosterone
in the presence of NAD. 11-HSD-2 activity was measured in
protein homogenates from renal cortex and distal colon. Protein
concentration was quantified colorimetrically using a Bio-Rad protein
assay kit. Protein homogenates from kidney (25 g/ml) and colon (50
g/ml) were incubated in duplicate at 37°C in 0.1 M Tris buffer, pH
7.6, 0.25 M sucrose, and 5 mM MgCl2 solution with NAD (0.5 mM),
[3H]corticosterone (10 nM), and unlabeled corticosterone (990 nM) in
the presence of 10 mM DTT (19). After 60 (kidney) and 240 min
(colon), the reaction was terminated by the addition of ethyl acetate,
and the organic phase was reduced to dryness under a stream of
oxygen-free nitrogen; steroids in the dried residue were dissolved in
the mobile phase (60:15:25 water-acetonitrile-methanol) and quanti-
fied by HPLC with online liquid scintillation counting as described
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previously (27). Conditions were optimized for each tissue to ensure
first-order kinetics.
Statistical Methods
Differences between two groups were analyzed using an unpaired
t-test, and variance was tested with an F-test. Differences between
more than two groups were estimated by ANOVA (treatment-series,
BDL rats). If data did not have a Gaussian distribution, a Mann-
Whitney U-test was used to test differences between two groups, and
differences between more than two groups were estimated with the
Kruskal-Wallis test. Levels of significance were P 	 0.05.
RESULTS
Characterization of Experimental Model of BDL in Rats
Five weeks after BDL, all rats displayed jaundice with
elevated bilirubin and hepatosplenomegaly (Tables 1 and 2).
Weight gain was slowed significantly by BDL in all series, and
organ weight-to-body weight ratios were significantly higher in
both compensated and decompensated BDL rats compared
with sham rats (Tables 1 and 2). Histopathological examination
of the livers after 5 wk of BDL showed fibrosis and septa
formation between portal triads and the central veins with
apparently normal liver tissue in between. Seven weeks after
BDL, the livers exhibited completely distorted architecture
with small regeneration nodules and severe fibrosis. About
80% of the rats accumulated ascites between 5 and 7 wk after
BDL (Table 1). This was associated with a mortality of
35%.
In the decompensated stage at 7 wk, plasma hemoglobin,
erythrocyte volume fraction, and thrombocytes were lower,
whereas the white blood cell count was elevated (Table 2).
Serum albumin concentration was lower in BDL rats, whereas
serum bilirubin was higher in all BDL groups compared with
Table 1. Basal characteristics of BDL and sham rats after 5 and 7 wk
5 wk 7 wk
Sham BDL Sham BDL
Initial number of rats 5 6 12 18
Mortality 0 0 0 7
Rats with/without ascites 0/5 0/6 0/12 8/3
Ascites volume, ml 0 0 0 19 (6–80)
Final number of rats 5 6 12 8
Preoperative weight, g 3055 2899 2335 2324
Final weight, g 36710 30818* 3447 3147*
Liver, g/100 g BW 3.20.08 6.40.8* 3.30.06 5.40.6
Spleen, g/100 g BW 0.200.01 0.60.05 0.210.01 0.710.04
Kidney, g/100 g BW 0.570.02 0.70.05* 0.610.02 0.740.02*
Heart, g/100 g BW 0.290.01 0.330.02*
All values are expressed as means  SE. *P 	 0.05; **P 	 0.01. BDL, bile duct ligated; sham, sham-operated control; BW, body weight.
Table 2. Effect of dexamethasone and K-canrenoate on organ weights, plasma electrolytes, blood cells, hormones,
and Na/K ratios in BDL compared with sham rats
Sham  Vehicle BDL  Vehicle BDL  Dexamethasone
BDL 
Canrenoate
Weeks after surgery 7 7 7 7
Initial number of rats 12 15 15 15
Mortality 0 5 7 5
Final number of rats 12 10 8 10
Preoperative weight, g 2628 2626 25110 2658
Final weight, g 38613 34610* 28510† 34314
Liver, g/100 g BW 3.80.14 7.60.6† 8.50.7 8.80.3
Spleen, g/100 g BW 0.170.02 0.730.03† 0.60.08 0.610.08
Kidney, g/100 g BW 0.610.02 0.740.02* 0.890.05 0.650.08
Heart, g/100 g BW 0.280.01 0.390.02* 0.420.03 0.340.03
Adrenal glands, mg/100 g BW 16.60.8 20.72.5 16.22.8 17.11.2
P-sodium, mM 1410.5 1410.5 1400.7 1400.5
S-creatinine, M 281.2 272.7 260.8 270.5
B-platelets, 109/liter 74378 37166† 370101 69388†
P-albumin, M 59910 41120† 49045 41925
B-leucocytes, 109/liter 50.5 282.9† 281.1 221.8
Hemoglobin, mM 10.30.1 8.40.4† 9.91.0† 8.60.3
B-hematocrit, % 470.5 401.7† 465.0† 401.7
Plasma osmolality, mosmol/kg H2O 2961.2 2971.2 2960.3 2980.8
S-bilirubin, M 20.2 14116† 16616 13114
P-aldosterone, nM 0.11 (0.03–0.34) 0.57† (0.19–2.70) 0.46 (0.19–1.14) 0.62 (0.33–2.04)
PRC, 105 GU/ml 4.8 (1.9–21.7) 18.7 (3.1–27.0) 1.9 (1.0–25.7) 5.7 (2.3–24)
Urine Na/K ratio 0.460.01 0.260.03† 0.440.04† 0.410.01*
Feces Na/K ratio 0.790.07 0.520.07† 0.240.03† 0.670.07*
Values are expressed as means  SE. Values for aldosterone and plasma renin concentrations (PRC) are geometric means. Differences between the three 7-wk
BDL groups were estimated with ANOVA. *P 	 0.05; †P 	 0.01.
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the sham group (Table 2). Experimental BDL thus led to
progressive histopathological changes in liver compatible with
cholestasis, which was associated with biochemical signs of
functional liver impairment, extracellular volume expansion,
and ascites.
Effect of BDL on Renin-Angiotensin-Aldosterone and
Corticosterone in Plasma and Tissue
In sham-operated control rats, plasma renin concentration
(PRC) was not different 5 and 7 wk after surgery (Fig. 1A).
Whereas there was an age-dependent decline in renocortical
renin mRNA expression between 5 and 7 wk, kidney renin
mRNA expression was not significantly different in BDL
rats compared with control. After 5 wk, the control was
100  12.6% and BDL was 96.1  18.3%, and after 7 wk,
the control was 100  13.9% and BDL was 87.5  21.0%.
In the BDL rats, PRC was significantly higher than controls
at 5 wk but fell to control level at 7 wk. There was no
obvious difference in the distribution pattern of renin-
positive cells along afferent arterioles from BDL rats at 7
wk compared with sham (data not shown). The plasma
aldosterone concentration was significantly elevated after
BDL for 7 wk, whereas corticosterone concentrations were
not significantly affected compared with sham-operated
controls (Fig. 1B). Urinary Na/K ratio and plasma K
level were significantly decreased after 7 wk BDL in series
2 (BDL 0.29  0.06 vs. sham 0.48  0.02, P 	 0.01; and
BDL 5.0  0.2 vs. 5.6  0.2 mM control, P 	 0.005,
respectively), indicating mineralocorticoid excess.
Effect of BDL on Tissue Expression Level and Cellular
Distribution of 11-HSD-2 in Kidney and Distal Colon of
Compensated and Decompensated Rats
Next, we explored whether 11-HSD-2 was changed by
BDL in kidney and distal colon. Renocortical 11-HSD-2
mRNA expression was not significantly different from sham
controls at 5 wk after surgery; the control was 100  8.7%
and BDL was 97  13.8%. In contrast, after 7 wk of BDL,
renocortical 11-HSD-2 mRNA, protein, and activity levels
were significantly lower compared with those of sham rats
(Fig. 2, A–C). Immunostaining of sham-control kidney sec-
tions for 11-HSD-2 displayed labeling associated with
distal convoluted tubules, connecting tubules, and collecting
ducts in cortex, whereas labeling of collecting ducts de-
clined progressively in outer medulla and was absent in
inner medulla and papilla, as previously described (Fig. 2D)
(19, 30). Intercalated cells in the collecting ducts were not
labeled. The overall distribution of 11-HSD-2 labeling in
kidney from BDL rats was similar, albeit with consistently
less intensity (Fig. 2D). In marked contrast to kidney, we
found that 11-HSD-2 mRNA levels were significantly
increased in distal colon after 7 wk of BDL (Fig. 3A).
Indeed, 11-HSD-2 mRNA expression was threefold ele-
vated in distal colon in the compensated phase after 5 wk of
BDL; control was 100  16.9% and BDL was 302  77.5%.
The mRNA findings were supported by immunolabeling
(Fig. 3C); however, there was no significant difference at
the protein level as shown by Western immunoblotting (Fig.
3B). 11-HSD-2 activity was low in distal colon compared
with kidney, and hardly any conversion was detectable in
either cirrhotic or control rats.
Effect of BDL on Expression and Distribution of ENaC in
Kidney and Distal Colon
To explore whether the change in 11-HSD-2 level in
kidney and perhaps colon had functional consequences, we
determined mRNA level and cellular localization of the key
MR-regulated target, the ENaC. In kidney cortex, all three
ENaC subunits were detected at significant levels. In BDL,
mRNA encoding the -subunit of ENaC was significantly
reduced in abundance, whereas expression of - and -sub-
units was unchanged (Fig. 2, E and F). In sham rats, only the
-subunit was reproducibly detected in distal colon with the
use of 40 g of total RNA for the hybridization. In contrast
to kidney, mRNA abundances for all three ENaC subunits
were significantly enhanced in distal colon of decompen-
sated BDL rats (Fig. 3D). Immunolabeling of kidney and
distal colon sections with an ENaC subunit-specific anti-
body showed a distinct distribution of immunoreactive pro-
tein that was similar to that observed with the 11-HSD-2
antibody. Thus, in kidney, ENaC labeling was associated
with distal convoluted tubules, cortical collecting ducts, and
outer medullary collecting ducts (Fig. 2G). There were no
obvious differences in distribution of immunoreactivity be-
tween sham and kidneys from BDL rats, but there was a
Fig. 1. Effect of bile duct ligation (BDL) on the renin-angiotensin aldosterone
system. A: plasma renin concentrations in rats followed for 5 and 7 wk (W).
Values are means  SE *P 	 0.05. B: plasma concentrations of corticosterone
and aldosterone after 7 wk compared with sham-operated controls (sham).
Values are means  SE. **P 	 0.05 vs. control.
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clear tendency that labeling signals were weaker in the BDL
kidneys (Fig. 2G). In distal colon, we did not detect any
significant immunolabeling signals for ENaC associated
with epithelium or other layers in sham-operated rats,
whereas ENaC immunoreactivity and fluorescence were
observed in crypt and surface epithelial cells in distal colon
from the decompensated BDL rats (Fig. 3E).
Effect of Dexamethasone and K-Canrenoate on Electrolyte
and Water Balance in Decompensated BDL Rats
In the next experiments, we tested whether the significant
changes in 11-HSD-2 in kidney resulted in glucocorticoid-
mediated effects on sodium balance. Dexamethasone, which
has a very low affinity for MR compared with corticosterone,
Fig. 2. Effect of 7 wk of BDL on 11-hydroxysteroid dehydrogenase type 2 (11-HSD-2) and epithelial sodium channel (ENaC) in kidney cortex. A–C:
renocortical expression of 11-HSD-2 mRNA (A) and protein (B) and 11-HSD-2 activity (C) compared with sham rats. Bars represent means  SE. *P 	 0.05
vs. sham; n  8–12 for RNA measurements, n  4 for protein determination, and n  6–7 for activity assay. D: distribution of immunoreactive 11-HSD-2
protein in kidney sections. Labeling was associated with connecting tubules and cortical and outer medullary collecting ducts in sham rats (left), and staining
was less intense in decompensated BDL rats (right). Bar, 50 m. E: results of a ribonuclease protection assay for ENaC -, -, and -subunit mRNAs in kidney
cortex from sham and BDL rats. F: quantitative evaluation of the protection assay in which ENaC subunit mRNAs in BDL rats (filled bars, n 8) were compared
with those in sham rats (open bars, n  12). Bars represent mean  SE counts per minute. *P 	 0.05. G: distribution of immunoreactive ENaC -subunit protein
in BDL kidney (right) compared with kidney from sham rat (left). Top, immunoreactive protein visualized with diaminobenzidine (DAB) as chromogen
substrate; bottom, micrographs with fluorescence detection.
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suppressed endogenous plasma corticosterone (Fig. 4D). The
effect of dexamethasone on Na, K, and water balance in
decompensated BDL rats was compared with the effect of
K-canrenoate, an MR antagonist. Dexamethasone prevented
the development of ascites as efficiently as K-canrenoate (Fig.
4A) and significantly reduced the volume of ascites (Fig. 4B).
Plasma ANP concentration reflects changes in extracellular
volume; it was significantly higher in the decompensated BDL
group compared with sham controls and decreased signifi-
cantly after treatment with both dexamethasone and K-can-
renoate (Fig. 4C). Plasma renin and aldosterone concentrations
were not affected by dexamethasone or K-canrenoate admin-
istration to BDL rats (Table 2). Next, we performed balance
studies by analyzing intake and fecal and renal excretion of
electrolytes and water (Table 3). By using special granulated
food and measuring both urinary and fecal excretions, we were
able to account for 100% of sodium and potassium intake.
Sodium. Sham control rats were in sodium balance (intake of
680  16 mol Na 100 g rat1 24 h1), and they excreted
85% of the daily sodium intake in the urine and 15% in feces
(Fig. 5, A–C). In contrast, the BDL rats at 7 wk were in positive
sodium balance (Fig. 5A). This was the result of a significant
decrease in the urinary sodium excretion to 55% of the intake
(Fig. 5B), which was not counteracted by any significantly
increased fecal sodium loss: 23% of intake (Fig. 5C). Treat-
ment with dexamethasone or K-canrenoate did not affect so-
Fig. 3. Effect of 7 wk of BDL on 11-HSD-2 and ENaC in distal colon. A and B: 11-HSD-2 mRNA (A) and protein levels (B) in distal colon in BDL rats
(n 5) compared with sham rats (n 5). Bars represent means SE. †P	 0.01 vs. sham. C: distribution of immunoreactive 11-HSD-2 protein in distal colon.
Immunoreactivity for 11-HSD-2 was associated with cytoplasm of surface epithelial cells in BDL rats and in single cells in the colon crypts (BDL), whereas
labeling was hardly detectable in sham rats. D, top: results of a ribonuclease protection assay for ENaC subunit mRNAs in distal colon from sham and BDL rats.
The penultimate lane shows that the RNA probe was completely digested in the absence of target mRNA (yeast tRNA was used instead), and the last lane shows
intact probes. Bottom, quantitative evaluation of the protection assay where ENaC subunit mRNAs from BDL rats (filled bars, n  5) were compared with those
from sham rats (open bars, n  6). Bars represent mean  SE counts per minute. *P 	 0.05; **P 	 0.01. E: distribution of immunoreactive ENaC -subunit
protein in distal colon from BDL rat (right) compared with distal colon from sham rat (left). Top, immunoreactive protein visualized with DAB as chromogen
substrate; bottom, micrographs with fluorescence detection.
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dium intake in the cirrhotic rats (Table 3). At baseline before
intervention, the three groups of BDL rats had similar electro-
lyte excretion. Treatment with dexamethasone or K-canrenoate
increased total sodium excretion significantly to 148  19 and
139  12% of intake, respectively, in the first 24 h after the
intervention (Table 3). After 48 h, sodium excretion was
increased to the same level as sham rats (sham vehicle, 99
4.5%; BDL  vehicle, 84  15%; BDL  dexamethasone,
110  28%; BDL  K-canrenoate, 91  25%) (Table 3). The
effect of intervention on sodium handling was different in
kidneys and intestine. Urinary sodium excretion was increased
by treatment with both dexamethasone and K-canrenoate (Fig.
5B), whereas the fecal sodium loss decreased in the dexameth-
asone group but not after K-canrenoate-treatment (Fig. 5C).
Thus dexamethasone stimulated intestinal sodium absorption
in BDL rats.
Potassium. The sham control rats were in potassium balance
(Fig. 5D). The decompensated group had a negative potassium
balance, indicating excess MR activation. Potassium loss was
caused by higher fecal loss, whereas urinary potassium excre-
tion was not different from control level. The fecal potassium
loss was decreased by treatment with K-canrenoate but not
dexamethasone (Fig. 5F). Of note, renal handling of potassium
was similar in all four groups and unaffected by treatments
(Fig. 5E). Thus excess potassium wasting occurred exclusively
through fecal losses in BDL rats. The time courses of absolute
values of potassium intake and outputs are shown in Table 3.
Water. Renal water excretion was similar in control and
decompensated 7-wk BDL groups but increased significantly
after treatment of the decompensated rats with dexamethasone
or K-canrenoate (Fig. 5H). Only the K-canrenoate-treated
group increased water intake (P 	 0.05) (Fig. 5G). The water
content in feces was similar in the sham  vehicle (57 
0.5%), BDL  vehicle (58  0.7%), BDL  dexamethasone
(57  0.8%), and BDL  K-canrenoate rats (55  0.4%). As
a consequence of a larger food intake, fecal water loss was
significantly higher in the sham  vehicle rats (1.7  0.04
ml 100 g rat1 24 h1) compared with the three BDL groups
that had identical fecal water losses (1.1  0.1 ml 100 g
rat1 24 h1; P 	 0.01).
Effect of Dexamethasone and K-Canrenoate on Urinary and
Feces Na/K Concentration Ratios
The urinary Na/ K ratio was significantly lower in de-
compensated BDL rats compared with sham-operated controls
(Fig. 6A). Treatment of the BDL rats with dexamethasone or
K-canrenoate led to a significant increase in urinary Na/ K
ratio to a level not different from that of sham-operated
controls. Feces Na/ K ratio was also significantly reduced in
the BDL rats compared with sham-operated controls. Treat-
ment with dexamethasone led to a further reduction of the feces
Na/ K ratio, whereas treatment with K-canrenoate led to a
significant increase in Na/K ratio compared with the de-
compensated BDL  vehicle rats (Fig. 6B).
Effect of Dexamethasone and K-Canrenoate on Plasma and
Urine Osmolality and Creatinine Clearance in
Decompensated BDL Rats
Plasma osmolalities were similar in all groups (sham 
vehicle, 296 1.2 mosmol/kgH2O; BDL vehicle, 297 1.2
Fig. 4. Effect of dexamethasone and K-canrenoate on extracellular volume
parameters in BDL rats. A: effect of dexamethasone (Dex) and K-canrenoate
(Can) on the incidence of ascites 7 wk after BDL. Bars represent the number
of rats; filled sections indicate the number of rats with ascites. B: effect of Dex
and Can on ascites volume in BDL rats after 7 wk compared with vehicle-
treated BDL rats (BDL  vehicle). Individual values are shown.*P 	 0.05;
**P	 0.01. C: effect of Dex (n 7) and Can (n 9) on plasma concentration
of atrial natriuretic peptide (ANP) in decompensated BDL rats after 7 wk. Bars
represent means  SE. *P 	 0.05 vs. BDL  vehicle. D: effect of Dex (n 
7) and Can (n  9) on plasma corticosterone concentration in BDL rats after
7 wk. Bars represent means  SE. *P 	 0.05 vs. BDL  vehicle.
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mosmol/kgH2O; BDL  dexamethasone, 296  0.3 mosmol/
kgH2O; BDL  K-canrenoate, 298  0.8 mosmol/kgH2O).
Urine osmolality decreased significantly in the K-canrenoate-
treated group as expected from the increase in water excretion
(BDL canrenoate, 0.8 0.1 mosmol/kgH2O, compared with
sham  vehicle, 1.6  0.1 mosmol/kgH2O, P 	 0.05; BDL 
vehicle, 1.5  0.2 mosmol/kgH2O, and BDL  dexametha-
sone, 1.5  0.2 mosmol/kgH2O). Osmolar clearance (Closm)
was lower in the BDL  vehicle compared with the sham 
vehicle group (12.0  1.3 vs. 16.7  1.2 l/min, P 	 0.05).
Closm increased to the control level after dexamethasone and
K-canrenoate (17.7  0.7 and 15.1  0.5 l/min, respec-
tively). Clcrea was higher in the sham  vehicle group (0.30 
0.03 ml min1 100 g body wt1) than in the decompensated
BDL  vehicle group (0.20  0.03 ml min1 100 g body
wt1). In the dexamethasone-treated BDL group, Clcrea was
increased to 0.32  0.03 ml min1 100 g body wt1, whereas
in the K-canrenoate-treated BDL group, Clcrea was unchanged
(0.25  0.03 ml min1 100 g body wt1).
Effect of Dexamethasone and K-Canrenoate on Weight Gain,
Organ Weights, and Blood Chemistry
Treatment with dexamethasone or K-canrenoate did not
correct the significantly slower rate of growth of BDL rats.
The dexamethasone-treated BDL rats actually had a signif-
icantly lower weight at completion of the study compared
with the K-canrenoate-treated BDL rats despite a similar
food intake and natriuretic effect (Table 2). This was prob-
ably caused by the overall catabolic effect of the potent
glucocorticoid. The organ weight-to-body weight ratios in
the decompensated BDL rats remained or were further
elevated after treatment with K-canrenoate or dexametha-
sone compared with sham controls. Hemoglobin and eryth-
Table 3. Effect of dexamethasone and K-canrenoate on the time courses for intake and renal and fecal excretion of sodium
and potassium in BDL rats
Basal Day 1 Day 2 Day 3 Day 4 Day 5 Average (Days 1–5)
Daily sodium intake, mol
Na100 g rat124
h1
Sham  vehicle 65826 69927 69820 68916 67320 63017 68016
BDL  vehicle 52141* 49353* 44943* 41554* 34655* 40759* 41454†
BDL  dexamethasone 52665 44448 45356 45364 46573 43672 46159
BDL  canreonate 59959 47540 51127 52118 50340 46537 49428
Urinary sodium excretion,
mol Na100 g
rat124 h1
Sham  vehicle 56624 60721 56240 60020 56427 53025 57419
BDL  vehicle 31656* 28648† 26245† 333110* 15842† 12532† 23844†
BDL  dexamethasone 39466 765119† 42867 31082 38580* 35161† 42770*
BDL  canreonate 39762 54334 35031 40732 40523* 37234† 40223*
Fecal sodium excretion,
mol Na100 g
rat124 h1
Sham  vehicle 9813 867 9913 1039 10211 9818 996
BDL  vehicle 12223 10522 11624 9720 8617 9425 9918
BDL  dexamethasone 10919 7012 659 487 5510 446 547*
BDL  canreonate 14217 10324 9419 9213 10415 9017 9914
Daily potassium intake,
mol K100 g
rat124 h1
Sham  vehicle 1,43056 151859 151843 149735 146244 137038 1,47733
BDL  vehicle 1,13290* 1071115* 97594† 902118† 752120† 884129† 899117†
BDL  dexamethasone 1,143140 964105 985121 985138 1011159 947156 1,001129
BDL  canreonate 1,270127 101285 108559 111443 104273 94365 1,04351
Urinary potassium
excretion, mol
K100 g rat124 h1
Sham  vehicle 1,26837 1,30651 1,22772 1,32832 1,24841 1,24931 1,27236
BDL  vehicle 99077* 89159† 86682† 84269† 74480† 608136† 80669†
BDL  dexamethasone 1,126117 1,188109 946120 982117 1,01096* 99485 95899
BDL  canreonate 1,111102 1,00872 1,02648 94850 99262 95656 98644
Fecal potassium excretion,
mol K100 g
rat124 h1
Sham  vehicle 13219 12611 14314 14014 14016 12316 13012
BDL  vehicle 18619 20432* 21735* 16621 17620 18829 19223*
BDL  dexamethasone 15614 24914 23122 19026 22143 21730 22021
BDL  canreonate 18518 14524 17417 15516 15515 13215 15215
Data are presented as absolute values per day and as averages of the 5-day period. Values are expressed as means SE. Statistical evaluation has been analyzed
on basal day and on 5-day averages. Differences between vehicle-treated sham and BDL groups were estimated with an unpaired t-test. Differences between BDL
rats were estimated by ANOVA. *P 	 0.05; †P 	 0.01.
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rocyte volume fractions were lower in the vehicle-treated
BDL and K-canrenoate-treated BDL groups but increased in
the dexamethasone-treated BDL group (Table 2). Plasma
sodium and creatinine levels were equal in all groups (Table
2). Plasma bilirubin concentration was similar in BDL rats
and in the BDL rats treated with K-canrenoate and dexa-
methasone.
DISCUSSION
In the present study, we used the rat model of BDL to study
mechanisms of sodium and water retention in the transition
from compensated to decompensated liver cirrhosis. The data
showed that augmented renal sodium reabsorption was respon-
sible for a positive sodium balance despite increased fecal
Fig. 5. Effect of dexamethasone and K-can-
renoate on sodium, potassium, and water bal-
ances in BDL rats. A and D: total sodium and
potassium balances were determined 7 wk after
surgery in vehicle-treated BDL and sham rats,
Dex-treated BDL rats, and Can-treated BDL
rats. B and C: urinary (B) and fecal (C) sodium
excretion was determined 7 wk after surgery in
vehicle-treated BDL and sham rats, Dex-
treated BDL rats, and Can-treated BDL rats. E
and F: urinary (E) and fecal (F) potassium
excretion was determined 7 wk after surgery in
vehicle-treated BDL and sham rats; Dex-
treated BDL rats, and Can-treated BDL rats. G
and H: water intake (G) and urine flow (H)
were determined 7 wk after surgery in vehicle-
treated BDL and sham rats, Dex-treated BDL
rats, and Can-treated BDL rats. All bars repre-
sent means SE from averages over the 5-day
period. Numbers of rats in each group are as
reported in Fig. 4 legend. *P 	 0.05; **P 	
0.01.
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sodium losses. The enzyme 11-HSD-2 was downregulated
in kidney, and suppression of endogenous corticosterone by
treatment with dexamethasone corrected the decreased uri-
nary Na/K ratio, augmented urinary sodium excretion,
and reduced ascites formation. This indicates that excess
activation of the MR by corticosterone contributes to the
exaggerated renal sodium reabsorption during decompensated
stages of BDL.
Consistent with reports from rats with carbon tetrachloride-
induced cirrhosis (12), we observed that ENaC mRNA expres-
sion in the kidney was unchanged or slightly reduced at the
same time as plasma aldosterone was elevated. Increased cell
surface expression of the ENaC subunits after MR activation
(28) may explain the increased renal ENaC activity despite
unchanged ENaC mRNA expression (2), or dysregulated ex-
pression and activity of aldosterone-induced/repressed proteins
may lead to prolonged surface expression of ENaC. In a recent
study, serum and glucocorticoid-inducible kinase-1, which
have a central role in recruitment of ENaC to the cell surface,
were unchanged in 4-wk BDL rats, whereas Nedd-4, a ubiq-
uitin ligase protein that promotes internalization and degrada-
tion of ENaC, was reduced 50% (44). During the develop-
ment of decompensation in the period from 5 to 7 wk, there
was a decrease in renin synthesis and secretion, whereas
plasma aldosterone concentration was significantly increased
in the decompensated rats at 7 wk. This could contribute to
increased sodium reabsorption.
In contrast to kidney, all ENaC subunits were markedly
elevated in distal colon of BDL rats. This upregulation corre-
lated with increased fecal potassium and sodium losses, sug-
gesting a shift to low-capacity, high-affinity NaCl transport.
Fecal NaCl excretion was decreased to control level by dexa-
methasone, but fecal potassium wasting was not. Thus sodium
and potassium handling were differentially changed in kidney
and distal colon with progression of bile duct-occlusive liver
disease.
Urinary Na/K ratio was decreased in the decompensated
BDL rats, which indicated a MR-mediated effect on the col-
lecting ducts. This was supported by the fact that administra-
tion of an MR antagonist, K-canrenoate, increased the urinary
Na/K ratio, normalized sodium balance, reduced the inci-
dence and severity of ascites, and led to suppression of the
plasma ANP concentration, which is an indicator of intravas-
cular volume. Several mechanisms may contribute to the acti-
vation of the MR. Plasma aldosterone concentration was sig-
nificantly increased after 7 wk of BDL compared with the
sham-operated controls. On the other hand, there also was a
significant fall in the expression of renal 11-HSD-2 in from 5
to 7 wk, when decompensation develops. This would allow
corticosterone to gain access to renal MR. In accordance with
this notion, we observed that suppression of plasma cortico-
sterone (but not aldosterone) concentration with dexametha-
sone corrected the urinary Na/K ratio, normalized sodium
balance, reduced the incidence and severity of ascites, and
suppressed plasma ANP concentration to a similar degree as
direct blockade of MR with K-canrenoate. A similar effect of
dexamethasone on urinary Na/K ratio was observed in mice
with targeted deletion of the 11-HSD-2 gene (25).
Dexamethasone binds to the MR in vitro with an affinity
close to that of glucocorticoids (20), suggesting that dexameth-
asone could act as a MR antagonist. However, dexamethasone
does not functionally bind to the renal MR in vivo (14, 16),
probably because of a high off-rate of dexamethasone bound to
the MR in contrast to the stable binding of dexamethasone to
the glucocorticoid receptor (21, 34). Furthermore, the sodium
transport response to dexamethasone in the mCCDcl1 cell line
is not inhibited by the MR antagonist spironolactone (17). Thus
a direct antagonist action of dexamethasone is less likely to
explain the present results. Dexamethasone increased creati-
nine clearance, suggesting that an increase in GFR and tubular
flow rate could increase distal potassium secretion and thereby
normalize the Na/K ratio. However, the absolute urinary
potassium excretion was not affected by dexamethasone treat-
ment, making this possibility less likely. Together, the data are
consistent with the hypothesis that inappropriate activation of
MR by corticosterone contributed to renal salt and water
retention in decompensated liver cirrhosis. This confirms the
functional significance of reduced renal 11-HSD-2 level,
observed in the present study during decompensation and in
previous studies during the early preascitic phase of liver
impairment (1, 10, 23, 24). Inhibition of 11-HSD-2 may be
mediated by the high concentration of bile acids (1, 31, 33, 37)
or other processes. However, it is interesting that the process
was fairly specific for the nephron and affected 11-HSD-2
mRNA and protein levels as well as enzyme activity. In this
line, licorice-based inhibitors have been suggested to down-
regulate 11-HSD gene transcription, although the molecular
mechanism is moot. This raises the intriguing possibility that
treatments to induce renal 11-HSD-2 activity as well as those
that block cortisol production may be useful in hepatic failure-
induced sodium and water retention.
Distal colon is another target for mineralocorticoids that has
not previously been investigated in the context of the BDL
model. The total balance studies showed a marked increase in
Fig. 6. Effect of dexamethasone and K-canrenoate on urinary and fecal
Na/K ratio in BDL rats. A: effect of Dex and Can on urinary Na/K ratio
in BDL compared with sham rats. B: effect of Dex and Can on fecal Na/K
ratio in BDL rats compared with sham rats. Values are shown as means  SE.
Numbers of rats in each group are as reported in Fig. 4. *P 	 0.05; **P 	
0.01.
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fecal NaCl losses after BDL, and in contrast to the kidney,
11-HSD-2 mRNA expression was significantly upregulated
in colon, whereas protein levels were unchanged. In addition,
we found an increased expression of ENaC as also observed in
the colon of portal vein-ligated rats (13). It has been hypoth-
esized that downregulation of renal 11-HSD-2 activity in
liver cirrhosis could be mediated by the high plasma concen-
tration of bile acids (1, 31, 33). The predominant mechanism of
sodium reabsorption in the normal distal rat colon is a low-
affinity, high-capacity electroneutral sodium transport through
combined Na/H and Cl/HCO3 exchangers that are stim-
ulated by glucocorticoids (4). In conditions with increased MR
activation, the transport mechanism of distal colon changes
from the low-affinity, high-capacity electroneutral sodium
transport to a high-affinity, low-capacity transport through
ENaC (5). The increased expression of ENaC in BDL rats is
consistent with such a transition. The electrogenic transport
through ENaC varies as a function of mineralocorticoid status.
Increased activation of ENaC results in a lumen-negative
potential, which favors leak of potassium back into the lumen.
This also is consistent with the observed 50% decrease in
intestinal sodium absorption in the cirrhotic rats and with the
stimulation of intestinal sodium absorption by dexamethasone,
which stimulates glucocorticoid receptors. In keeping with this
interpretation, dexamethasone did not correct the intestinal
potassium loss. The increased ENaC expression in colon of
decompensated rats was associated with a higher potassium
loss into feces as one would predict from the transport char-
acteristics. This finding could explain the lower plasma potas-
sium concentration, which was not explained by potassium loss
in the urine. In keeping with this, intestinal potassium loss, but
not sodium loss, was corrected by treatment with K-canreno-
ate. Thus, under the conditions investigated in the present
study, changes in intestinal potassium transport account fully
for the effects on total potassium homeostasis in BDL rats.
We conclude that development of liver cirrhosis in the BDL
rat is associated with sequential changes in the renin-angioten-
sin-aldosterone system, but our results suggest that renal down-
regulation of 11-HSD-2 and inappropriate activation of so-
dium absorption by glucocorticoids plays a major functional
role for development of overt decompensation. In addition, our
results point to an unexpected regulatory role of colon for
potassium and sodium homeostasis in liver cirrhosis.
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